← All trials
NCT05107674
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2021
- Primary completion
- Aug 31, 2024
- Completion date
- Feb 28, 2025
- First posted
- Nov 4, 2021
- Last posted
- Nov 4, 2021
- Enrollment
- 336
- Arms / groups
- 9 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Nurix Therapeutics, Inc.Lead sponsor
- Nurix Therapeutics, Inc.Study director
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Carcinoma, Ovarian Epithelial
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Transitional Cell
- Uterine Cervical Neoplasms
- Esophageal Neoplasms
- Melanoma
- Mesothelioma
- Stomach Neoplasms
- Colorectal Neoplasms
- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Prostatic Neoplasms, Castration-Resistant
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.